Regresa al Registro Simple

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorBurotto, Mauricio
dc.contributor.authorZvirbule, Z.
dc.contributor.authorMochalova, A.
dc.contributor.authorRunglodvatana, Y.
dc.contributor.authorHerraez-Baranda, L.
dc.contributor.authorLiu, S.N.
dc.contributor.authorFELIP, ENRIQUETA
dc.date.accessioned2023-08-02T07:37:21Z
dc.date.available2023-08-02T07:37:21Z
dc.date.issued2023-08
dc.identifier.citationBurotto M, Zvirbule Z, Mochalova A, Runglodvatana Y, Herraez-Baranda L, Liu SN, et al. IMscin001 Part 2: a randomised phase III, open-label, multicentre study examining the pharmacokinetics, efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous administration in previously treated locally advanced or metastati. Ann Oncol. 2023 Aug;34(8):693–702.
dc.identifier.issn0923-7534
dc.identifier.urihttps://hdl.handle.net/11351/10031
dc.descriptionCáncer de pulmón de células no pequeñas; Farmacocinética; Subcutáneo
dc.language.isoeng
dc.publisherElsevier
dc.relation.ispartofseriesAnnals of Oncology;34(8)
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceScientia
dc.subjectAvaluació de resultats (Assistència sanitària)
dc.subjectPulmons - Càncer - Tractament
dc.subjectInjeccions hipodèrmiques
dc.subjectAnticossos monoclonals - Ús terapèutic
dc.subject.meshCarcinoma, Non-Small-Cell Lung
dc.subject.mesh/drug therapy
dc.subject.meshInjections, Subcutaneous
dc.subject.meshAntibodies, Monoclonal
dc.subject.meshTreatment Outcome
dc.titleIMscin001 Part 2: a randomised phase III, open-label, multicentre study examining the pharmacokinetics, efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous administration in previously treated locally advanced or metastatic non-small-cell lung cancer and pharmacokinetics comparison with other approved indications
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1016/j.annonc.2023.05.009
dc.subject.decscarcinoma de pulmón de células no pequeñas
dc.subject.decs/farmacoterapia
dc.subject.decsinyecciones subcutáneas
dc.subject.decsanticuerpos monoclonales
dc.subject.decsresultado del tratamiento
dc.relation.publishversionhttps://doi.org/10.1016/j.annonc.2023.05.009
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Burotto M] Centro de Investigación, Clínica Bradford Hill, Santiago, Chile. [Zvirbule Z] Latvian Oncology Center, Riga Eastern Clinical University Hospital, Riga, Latvia. [Mochalova A] Department of Antitumor Drug Therapy, MEDSI Clinical Hospital, Moscow, Russia. [Runglodvatana Y] Faculty of Medicine, Vajira Hospital, Bangkok Metropolitan University, Bangkok, Thailand. [Herraez-Baranda L] Product Development Medical Affairs Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland. [Liu SN] Clinical Pharmacology, Genentech, Inc., South San Francisco, USA. [Felip E] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Clinical Research Department, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
dc.identifier.pmid37268157
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Regresa al Registro Simple